Shares of Evolent Health (NYSE:EVH) plummeted by 32.11% in after-hours trading on November 7, 2024, following the release of the company's disappointing third-quarter financial results and lower full-year guidance.
For the third quarter, Evolent Health reported an adjusted loss per share of $0.27, missing analysts' consensus estimate of $0.34 earnings per share by a wide margin. The company's revenue for the quarter came in at $621.4 million, slightly lower than the expected $627.2 million.
Evolent Health also lowered its full-year 2024 adjusted EBITDA guidance to a range of $160 million to $175 million, down from its previous expectations. The company cited challenges in certain areas of its business for the disappointing performance and reduced outlook.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.